<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Tedavi sonuçları &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tedavi-sonuclari/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Jan 2026 13:33:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Tedavi sonuçları &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Repurposing Drugs to Enhance Prostate Cancer Outcomes</title>
		<link>https://bioengineer.org/repurposing-drugs-to-enhance-prostate-cancer-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 13:33:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Hasta katılımı` **Seçimlerin Açıklaması:** 1. **İlaç yeniden kullanımı (Drug repurposing):** Makalenin ana konusu bu str]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: `İlaç yeniden kullanımı]]></category>
		<category><![CDATA[Klinik araştırmalar]]></category>
		<category><![CDATA[Prostat kanseri tedavisi]]></category>
		<category><![CDATA[Tedavi sonuçları]]></category>
		<guid isPermaLink="false">https://bioengineer.org/repurposing-drugs-to-enhance-prostate-cancer-outcomes/</guid>

					<description><![CDATA[In the rapidly evolving landscape of oncology, the innovative approach of drug re-purposing has emerged as a promising avenue for improving patient outcomes, particularly in the management of prostate cancer. This methodology, which involves the use of existing medications for new therapeutic purposes, holds the potential to streamline the drug development process. Not only does [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320307</post-id>	</item>
		<item>
		<title>Comorbidities Shape Anaplastic Thyroid Cancer Treatment Outcomes</title>
		<link>https://bioengineer.org/comorbidities-shape-anaplastic-thyroid-cancer-treatment-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 23 Dec 2025 19:14:35 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Anaplastik tiroid kanseri]]></category>
		<category><![CDATA[Kişiselleştirilmiş Tıp]]></category>
		<category><![CDATA[Komorbiditeler]]></category>
		<category><![CDATA[Multidisipliner ekipler **Kısa Açıklama:** 1. **Anaplastik tiroid kanseri:** Makalenin temel konusu. 2. **Komorbiditeler:** Araştırmanın ana odağı ve tedavi sonuçlar]]></category>
		<category><![CDATA[Tedavi sonuçları]]></category>
		<guid isPermaLink="false">https://bioengineer.org/comorbidities-shape-anaplastic-thyroid-cancer-treatment-outcomes/</guid>

					<description><![CDATA[Anaplastic thyroid cancer (ATC) remains one of the most aggressive forms of thyroid malignancies, characterized by rapid progression and poor prognosis. Recent research by Augustin and colleagues has illuminated the significant impact of comorbidities on treatment management and prognosis for patients diagnosed with this formidable disease. ATC, although rare, poses severe challenges not only due [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">310703</post-id>	</item>
	</channel>
</rss>
